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Prevention of mother-to-child transmission of HIV 
programme: Low vertical transmission in KwaZulu-Natal, 
South Africa  
Rosemary Geddes, Stephen Knight, Sandy Reid, Janet Giddy, Tonya Esterhuizen, Candice Roberts
At the United Nations General Assembly Special Session 
(UNGASS) on HIV/AIDS in 2001, member states committed 
themselves to the goal of reducing the proportion of infants 
infected with HIV by 20% by 2005 and by 50% by 2010.1 During 
2005 an estimated 700 000 children were newly infected with 
HIV, the vast majority in sub-Saharan Africa through mother-
to-child transmission (MTCT).2 In South Africa, a country with 
an antenatal HIV seroprevalence of 30.2%,3 the prevention of 
mother-to-child transmission (PMTCT) programme covers 
less than one-third of the country and to date ‘dual therapy’ 
(zidovudine (AZT) during pregnancy and nevirapine at 
delivery) is still not available in the public sector.4
The efficacy of single-dose nevirapine in PMTCT of HIV in 
the HIVNET012 trial was 11.9% (95% confidence interval (CI) 
8.2 - 15.7).5 The generalisability of trial results to the general 
population can be difficult.6-8 The challenges with extended 
prophylactic regimens, when PMTCT is integrated into existing 
health systems and monitoring to evaluate whether they have 
the desired effect, are even greater. 
The operational effectiveness of PMTCT programmes 
in South Africa is described in three studies,6,9,10 only one 
reporting on a site where prophylactic regimens contain more 
than just single-dose nevirapine.10 The 2002 evaluation of 
South Africa’s PMTCT of HIV at 18 sites reported that 56% 
of antenatal attendees were tested. The prevalence of HIV 
infection was 30% and only 55% of these women received 
nevirapine, while 99% of HIV-exposed newborns received 
nevirapine. Half of infants born to HIV-infected mothers 
were followed up and 18% tested positive for HIV.6 A lower 
vertical transmission rate of 8.7% at 6 weeks was reported from 
Coronation Women and Children’s Hospital in Johannesburg in 
2002.9 The MTCT rate reported from Khayelitsha in Cape Town 
in 2003 was 8.8% (95% CI 6.2 - 10.9) when women were given 
AZT from 34 weeks’ gestation.10  
A study in KwaZulu-Natal (KZN) used dry blood spot 
testing at immunisation clinics to estimate the prevalence 
of HIV.7 Despite the availability of nevirapine the vertical 
transmission rate of HIV was estimated at 20.8% (CI 18.2 - 
23.6) in 6-week-old infants. In 2005 the HIV prevalence among 
antenatal clinic attendees in KZN was estimated at 39.1%, the 
highest in the country.3 Here, more than almost anywhere else, 
effective PMTCT programmes are needed in order to achieve 
UNGASS goals.
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Objective. To describe the operational effectiveness of the 
prevention of mother-to-child transmission (PMTCT) of HIV 
programme at McCord Hospital during the period 1 March 
2004 - 31 August 2005. 
Design. Observational cohort study.
Setting. McCord Hospital, Durban, South Africa.
Subjects. Antenatal patients attending the PMTCT clinic.
Measurements and results. During the 18 months all 2 624 
women (100%) attending the antenatal clinic received HIV 
counselling, resulting in 91% (2 388) being tested for HIV. 
The prevalence of HIV in the total cohort was 13% (95% 
confidence interval (CI) 11.6 - 14.2). 
Of the HIV-positive mothers 302 (89%) completed their 
pregnancy at the hospital, and in this group there were 3 
intrauterine deaths, 1 miscarriage, 1 maternal death (with the 
baby in utero) and 297 live births with 1 early neonatal death. 
Only 11% (36 out of 338) were lost to follow-up. A quarter 
(668) of the partners of all women attending the antenatal 
clinic were tested for HIV. 
Delivery in 70% (209) of live births was by caesarean 
section. Nevirapine was administered to 98% (290) of live 
babies and 75% (224) received zidovudine (AZT) as well. 
The 6-week polymerase chain reaction (PCR) baby test 
uptake was 81% (239 out of 296 live babies). Of those tested, 
2.9% (95% CI 1.3 - 6.2) tested HIV positive.  
Conclusion. Despite challenges faced by PMTCT providers 
in a resource-constrained setting, this state-aided hospital 
provides a comprehensive and integrated service and has 
achieved outcomes that compare favourably with those in the 
developed world.
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Owing to poor monitoring in PMTCT programmes, 
operational research in areas of high HIV prevalence is 
necessary to determine outcomes and provide answers to 
service delivery problems. This study reports on the outcomes 
achieved in a PMTCT programme in KZN where extended 
PMTCT regimens have been introduced.
Methods
Setting
McCord Hospital is a state-aided hospital in Durban, South 
Africa, serving patients from a wide catchment area. It offers 
patients an affordable alternative to overcrowded public 
services and expensive private medicine. Funding for the 
hospital comes from the KZN Department of Health (43%), 
patient fees and grants. In 2004 McCord received funding from 
the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) to 
expand and improve the PMTCT programme. 
PMTCT programme
The PMTCT programme is integrated into general antenatal 
services. Staff comprise one medical officer, two nurses, two 
counsellors, four midwives, one administrative assistant and an 
obstetrician. Four first-visit midwives are trained as counsellors 
to reduce the number of steps in the care pathway. Most staff 
have other duties and are not dedicated to PMTCT only. Since 
2004 the programme has been part of the KZN provincial 
PMTCT programme.
Counselling and testing
Voluntary counselling and testing (VCT) is conducted on 
an individual basis. Since February 2005, pre- and post-test 
counselling and testing have been done by the same midwife 
to improve integration. A rapid HIV test (Abbott Determine) 
is used and positive results are confirmed with a second rapid 
test (Smart Check). The test results are given as part of the 
initial visit. HIV-negative women are offered a repeat test after 
3 months.
Partner testing
All pregnant women are encouraged to bring their partners to 
the antenatal clinic. Partners are also offered testing and, if HIV 
positive, are referred to Sinikithemba, the HIV clinic at McCord 
Hospital. Disclosure is encouraged. Psychology services 
are available for couples experiencing serious relationship 
difficulties due to discordancy.
Laboratory monitoring and follow-up
Early in the study period CD4 counts and viral loads were 
not being done on all women, but this improved and now all 
HIV-positive women have a routine CD4 count after post-test 
counselling. A goal of the PMTCT programme is to identify 
women who need highly active antiretroviral treatment 
(HAART) (CD4 <200 cells/μl) for their own health and to fast-
track them onto treatment. Women with a CD4 count above 200 
cells/μl have their viral load measured to determine the most 
suitable PMTCT prophylaxis. Furthermore, all HIV-positive 
women have their viral load measured at 36 weeks’ gestation 
to determine the most appropriate mode of delivery. 
CD4 lymphocyte counts are performed by flow cytometry 
(Becton Dickinson) and viral load is measured by means of 
the Amplicor HIV-1 Monitor PCR test (Roche), with a lower 
limit of detection of <50 copies of HIV RNA/ml. A private 
laboratory service is utilised for these tests. A polymerase 
chain reaction (PCR) test is done on HIV-exposed babies whose 
mothers return for the 6-week postnatal check. The PCR results 
are given 1 week later when the mother returns for a further 
appointment. The paediatrician is immediately informed of 
HIV-positive babies so they can be enrolled in the Sinikithemba 
children’s programme. 
Clinical guidelines
Over the 18-month period the McCord PMTCT guidelines were 
based on evidence from international studies.11,12 If the CD4 
count was below 200 cells/μl, women were started on HAART. 
If it was >200 cells/μl, women received either HAART, AZT 
antenatally and nevirapine at onset of labour, or nevirapine 
alone at onset of labour. The decision was based on viral load, 
gestational age at presentation and patient finances. After 
June 2005, when more funding became available, women with 
a CD4 of >200 cells/μl received either AZT antenatally and 
single-dose nevirapine at the onset of labour (if viral load  
<1 500 copies/ml) or prophylactic HAART during pregnancy 
(if viral load >1 500 copies/ml).
HIV-infected pregnant women were counselled about infant 
feeding options and assisted in deciding whether formula 
feeding would be acceptable, feasible, affordable, sustainable 
and safe for them. If not, exclusive breastfeeding for 6 months 
was recommended.
Study design and population
An observational cohort design was utilised. Data were 
collected retrospectively and prospectively since the study 
began in June 2005 and continued till all the women had 
delivered. The study population was all pregnant women 
attending McCord Hospital for their first antenatal visit from 
the beginning of March 2004 till the end of August 2005. 
Data sources
Quantitative and qualitative data were collected from antenatal 
clinic charts, electronic records, review of routine monthly 
PMTCT data, record and document review, individual key 
informant interviews with staff members and participant 
observation.
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Statistical analysis
Data were captured and analysed using SPSS 13 (SPSS Inc., 
Chicago, Ill). EpiCalc 200013 was used to calculate bivariate 
relative risks and 95% confidence intervals.  
Ethics 
The study was approved by the University of KwaZulu-Natal 
Biomedical Research Ethics Committee (reference number 
H055/05) and the McCord Hospital ethics committee. No 
individual patient consent was deemed necessary as it was an 
anonymous record review. 
Results
Testing, seroprevalence and follow-up
During the 18 months all 2 624 women (100%) attending the 
antenatal clinic received counselling, and 91% (2 388) of them 
were tested for HIV. Sixty-nine per cent (1 811) were tested at 
McCord Hospital, 577 (22%) were tested elsewhere and 236 
(9%) were not tested. Of women attending the clinic, 338 (13%) 
were HIV positive (95% CI 11.6 - 14.2). Of these 338 women, 
89% (302) completed their antenatal care at McCord and 36 
(11%) were lost to follow-up. 
Demographics and partner testing
The mean age of the HIV-infected cohort was 28 years (range 
18 - 40 years) and 24% were married. Twenty-five per cent of 
partners (668) were tested for HIV. The HIV status of 113 (37%) 
partners of the 302 HIV-positive women who completed their 
care at McCord was disclosed to the service. It was found that 
there were 42 (37%) discordant couples. 
CD4 counts and viral loads
The mean gestation at first visit was 30 weeks (range 14 - 41 
weeks). CD4 counts were done on 262 women, with 67 (26%) 
having a CD4 count of <200 cells/μl and 195 (74%) ≥200 cells/
μl; the median CD4 count was 293 (interquartile range (IQR) 
195 - 451). Initial viral loads were done on 166 women but 36-
week viral loads were only done on 121 women. The median 
viral load at first presentation was 3.9 logs (IQR 3.1 - 4.6) or  
7 787 copies/ml (IQR 1 403 - 39 856). At 36 weeks’ gestation 
the median viral load was <50 copies/ml (IQR <50 - 558) or 1.7 
logs (IQR 1.7 - 2.7). 
Prophylaxis regimens
The regimens of 293 women (97% of the 302) were documented 
(Fig. 1). Of the 130 women (44%) who received HAART during 
pregnancy, 121 (93%) were started before or at 36 weeks’ 
gestation. Seven were started after 36 weeks and in 2 cases 
the gestation was not documented. Sixty per cent (77) of the 
women who received HAART had CD4 counts ≥200 cells/μl.
In 14 cases in which two antiretroviral drugs had been given 
during pregnancy, these were started by private doctors before 
the patient came to McCord Hospital. 
Baby outcomes
In the group of 302 HIV-positive mothers there were 3 intra-
uterine deaths, 1 miscarriage, 1 maternal death (with baby in 
utero) and 297 live births. One baby died shortly after birth. Of 
the live births 70% (209) were by caesarean section. Of the live 
babies, 290 (98%) received nevirapine after birth and 76% (224) 
also received AZT. In 6 cases (2%) there was no record of the 
baby receiving any antiretroviral therapy.
The 6-week PCR baby test uptake was 81% (239 of 296 live 
babies). Of those tested, 2.9% (95% CI 1.29 - 6.19) (7 babies) 
were HIV positive.  Of the 296 mothers questioned after 
delivery, 93% planned to formula feed. 
Risk of MTCT of HIV
Although the sample size was low and the study was not 
powered for it, bivariate analysis was performed to determine 
risk factors for transmission. The only significant (p<0.05) risk 
factors were found to be a first antenatal booking later than 
36 weeks’ gestation, a CD4 count in the mother less than 200 
cells/μl, and the baby receiving nevirapine only as opposed 
to nevirapine and AZT (Table I). As expected, the lowest 
prevalence of MTCT of HIV was in mothers on HAART (1.8%; 
95% CI 0.3 - 6.8) and the highest in mothers who received 
single-dose nevirapine only (8.2%; 95% CI 3.1 - 18.8). The 
incidence risk ratio of a baby being infected with HIV was 5.9 
(95% CI 1.1 - 31.1) if the mother’s CD4 count was less than 200 
cells/μl compared with more than 200. If the baby received 
nevirapine only as opposed to nevirapine and AZT, the 
incidence risk ratio was 5.3 (95% CI 1.2 - 22.7).
Discussion
The McCord Hospital PMTCT programme has achieved a 
number of positive outcomes in its first 18 months. As in many 
sites, the number of antenatal clients counselled is very high. 
In addition, in this programme 91% of antenatal clients’ HIV 
Fig. 1. The PMTCT prophylaxis regimens of HIV-infected pregnant 
women (N=293) attending the McCord Hospital PMTCT programme 
from March 2004 to August 2005.
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status is known through testing at McCord or elsewhere, which 
compares favourably with results in the developing world.14-16 
The McCord PMTCT programme follow-up of mothers is 
good, with almost 90% completing their care at the service. In 
scaling up a nevirapine-based programme in Lusaka, Zambia, 
patient attrition and non-adherence were major sources of 
inefficiency.17
Unpublished data from a situational analysis of PMTCT 
done in KwaZulu-Natal showed that 84% of health care 
workers agreed that men should be involved in the maternal 
health of their partners. A study in Uganda showed that at a 
routine antenatal service only 1.8% of partners tested for HIV.18 
At McCord Hospital just over a quarter of partners are testing 
and discordant couples are being identified and counselled. 
A very high percentage (97%) of mothers received 
prophylaxis, the most common being HAART, and 98% of 
babies received prophylaxis. This is a higher proportion than 
in most developing countries where studies have been done. In 
the Dominican Republic 89% of mothers and 98% of children 
received ARV prophylaxis.19 In the Ukraine 91% of HIV-
positive women received ARV prophylaxis for PMTCT.14 In 
Cameroon, the prevalence of maternal prophylactic treatment 
increased from 46% in 2004 to 86% in 2005.15 In the scale-up 
in Lusaka, Zambia, in 2002 nevirapine had been taken by 57% 
of mothers and 40% of babies. In South Africa as a whole 61% 
of HIV-infected women and 47% of exposed babies receive 
nevirapine prophylaxis.16 
Follow-up of infants is a problem. At Coronation Hospital 
more than one-third of infants were never brought back for 
follow-up and more than 70% were lost to follow-up by 4 
months of age.9 In KZN problems have been experienced 
with PCR testing of babies. An Integrated Management of 
Childhood Illnesses (IMCI) review (unpublished data) in 2005 
revealed that only 47 of 209 clinic managers were able to report 
on the percentage of babies PCR tested. Many clinics had 
stopped PCR testing because of the long turnaround time. The 
6-week follow-up for PCR testing of babies at McCord is just 
over 80%. The 1-week turnaround of the PCR test is achieved 
because the midwife who is responsible for monitoring obtains 
all the results in time for the mothers’ return visits. 
The low transmission rate to babies compares with rates 
achieved in sites in developed countries. The fact that 44% 
received HAART contributed to this, and the group cannot 
be compared with sites providing nevirapine only. The need 
to educate mothers to attend for their first antenatal booking 
before 36 weeks’ gestation is highlighted by the results of this 
study, as are the advantages of a higher CD4 count.
Limitations
Selection bias
This study may have been subject to selection bias, since 
11% of the HIV-infected women were lost to follow-up and 
may have been systematically different in some way to those 
studied. Furthermore, since McCord Hospital charges a 
user fee, patients attending may be socio-economically and 
educationally better off than those attending public facilities. 
This may influence health and compliance and the results 
may therefore not be generalisable to the general antenatal 
population of South Africa. 
Information bias
This study relied on data collected for routine monitoring. 
There may have been errors in written and electronic records.  
Table I. Risk of transmission by regimen and by risk factor in the McCord Hospital PMTCT programme,  
March 2004 - August 2005
Category of antiretroviral prophylaxis             N          % positive for HIV          95% CI
Overall rate of transmission             239                          2.9          1.3 - 6.2
Nil prophylaxis                  2                             0
Nevirapine only during labour              61                           8.2        3.1 - 18.8
AZT in pregnancy plus nevirapine during labour             45                             0
Dual therapy in pregnancy plus nevirapine during labour            14                             0
HAART               114                          1.8         0.3 - 6.8
AZT intravenously during labour                1                             0
Prophylaxis method not certain                 2                             0
Risk ratio of transmission         Risk ratio             p (Fisher’s exact)         95% CI
Married v. single (N=199)             1.22       0.682      0.25 - 6.11
Maternal age >25 yrs v. ≤25 yrs (N=170)            3.11       0.425     0.38 - 25.20
Partner status positive v. negative (N=105) Cannot calculate due to zero value      0.279
Gestation first booking >36 wks v. ≤36 wks (N=231)          4.81       0.048    0.95 - 24.24
CD4 count in mother <200 v. ≥200 (N=220)           5.86       0.038    1.10 - 31.12
NVD v. caesarean section (N=238)            1.66       0.680      0.38 - 7.24
Prophylaxis in babies NVP v. NVP and AZT (N=237)          5.25       0.033    1.22 - 22.68
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Confounding
The rate of transmission was very low; with only 7 babies who 
tested positive, low power was therefore achieved in analysis 
to determine risk factors for transmission, making multivariate 
analysis impossible. The risk ratios and transmission risks 
are therefore from crude bivariate analysis only and could be 
subject to confounding that could not be controlled for in the 
study.  
Conclusion and recommendations
This programme has done remarkably well at implementing 
PMTCT of HIV in a developing country with limited resources. 
It has managed to maintain its success despite changing and 
extended regimens. The service offered is comprehensive and 
integrated. It has achieved reduction of the rate of transmission 
to babies to 2.9% during the first 18 months while the 
programme was still evolving. 
Despite the successes, areas of the McCord PMTCT 
programme need attention. The low breastfeeding rate is 
of concern. Over 90% of women choose to formula feed; 
however, these babies are not specifically followed up to assess 
mortality or illness, particularly due to diarrhoeal disease. 
This is important to determine how accurate the infant feeding 
counselling is in flagging women who are not appropriate for 
formula feeding. 
Although they are referred on to the adult HIV clinic, it is 
unclear how many mothers who need HAART continue with 
these services. The incentive for HIV-positive mothers to obtain 
care and treatment is great during pregnancy but possibly 
wanes once the baby is born and found to be HIV negative. 
More should be done to monitor this and keep these women 
engaging with the services. Women who received short-course 
HAART during pregnancy for PMTCT prophylaxis (60% of 
those on HAART) should be monitored in order to start them 
on ARV therapy when their CD4 counts reach the treatment 
threshold.
Finally, not only the HIV-positive but also the negative 
babies need to be monitored over time. In this way the 
medium- and longer-term effects of PMTCT interventions can 
be evaluated and the safety of strategies improved. 
We are grateful to Candace Westgate, Hiliary Plioplys, Kristie 
Nixon and Chantelle Young for their assistance with data 
collection, Professor Quarraisha Abdool Karim and Professor 
Myra Taylor for commenting on the manuscript, and the McCord 
Hospital manager, Helga Holst, for advice and support.
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